Aktis Oncology (NASDAQ:AKTS - Get Free Report) Director Helen Susan Kim purchased 835,000 shares of the firm's stock in a transaction that occurred on Monday, January 12th. The shares were acquired at an average cost of $18.00 per share, with a total value of $15,030,000.00. Following the completion of the transaction, the director directly owned 5,671,825 shares of the company's stock, valued at $102,092,850. The trade was a 17.26% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Aktis Oncology Price Performance
AKTS stock opened at $21.75 on Tuesday. The firm has a market capitalization of $3.36 billion, a price-to-earnings ratio of -58.78 and a beta of 1.91. The company has a debt-to-equity ratio of 1.00, a quick ratio of 0.28 and a current ratio of 0.32. Aktis Oncology has a 1-year low of $19.33 and a 1-year high of $29.16.
Aktis Oncology News Summary
Here are the key news stories impacting Aktis Oncology this week:
- Positive Sentiment: Multiple large insider purchases signal management and major investors are backing the IPO — Ecor1 Capital bought 2,222,222 shares at $18 (~$40M) and increased its stake by ~104%, and director Helen Susan Kim (and affiliated Vida Ventures II) purchased 835,000 shares each at $18 (~$15M each), materially raising insider ownership. Filings show these are sizeable commitments from insiders. Ecor1 SEC Filing Helen Kim SEC Filing Vida Ventures SEC Filing
- Positive Sentiment: Strong IPO backing and proceeds: Aktis completed one of the largest recent biotech IPOs, raising about $318M and drawing a $100M anchor purchase from Eli Lilly — adding strategic validation and capital to advance clinical programs. MSN: Aktis IPO raised $318M MarketBeat IPO coverage
- Neutral Sentiment: Market context — Aktis’ IPO is being watched as an early test of biotech IPO appetite in 2026; broader market reception to recent small biotechs (and other January listings) will influence follow‑on trading. PharmaLetter: IPO tests market BioSpace: broader IPO activity
- Negative Sentiment: Company risk profile — Aktis is clinical‑stage and pre‑revenue, with tight liquidity ratios (low current/quick ratios) and leverage noted in public data; those fundamentals increase downside risk if clinical or commercialization timelines slip. MarketBeat: AKTS stock & financials
Aktis Oncology Company Profile
(
Get Free Report)
Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.
The company's activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
